Conclusion
For this rapidly evolving pandemic, the development of a specific
antiviral agent against the virus is of course what is needed, but
series of preclinical trials before any novel agent becomes available
for clinical use makes it an improbable option. Thus, the need of the
hour would be to assess the available armoury of drugs and use them in
defence against the current enemy.